Genetic basis of atherosclerosis: Part II - Clinical implications
Genetic basis of atherosclerosis: Part II - Clinical implications
复制标题
DOI：
10.1161/01.cir.0000143098.98869.f8
复制
发表时间：
2004-10-05
期刊：
影响因子：
37.8
通讯作者：
Fonarow, GC
中科院分区：
文献类型：
--
作者：
Lusis, AJ;Fogelman, AM;Fonarow, GC
抑制LDL捕获、LDL氧化和炎症的恶性循环。Navab等人6已经证明，短的合成两亲性螺旋，类似于apoAI中的那些，当口服给药于小鼠或猴子时，对动脉粥样硬化产生强大的保护作用。另一个有希望的治疗靶点是白三烯途径。正如本综述第一部分所讨论的，遗传研究表明5-脂氧合酶（5-LO）与小鼠和人类的动脉粥样硬化易感性有关，7最近的研究表明，白三烯代谢中其他酶的多态性也与CHD有关。8 5-LO多态性最初与哮喘有关，各种白三烯合成抑制剂被广泛用于治疗哮喘。因此，这些抑制剂也可以防止CHD的发展，可能为针对风险因素（如血脂和血压）的药物提供有用的补充。
inhibiting the vicious cycle of LDL trapping, LDL oxidation, and inflammation. Navab et al6 have demonstrated that short, synthetic amphipathic helices, similar to those in apoAI, exert powerful protective effects against atherosclerosis when administered orally to mice or monkeys. Another promising therapeutic target is the leukotriene pathway. As discussed in Part I of this review, genetic studies implicated 5-lipoxygenase (5-LO) in atherosclerosis susceptibility in mice and then humans, 7 and recent studies suggest that polymorphisms of other enzymes in leukotriene metabolism also are associated with CHD. 8 5-LO polymorphisms were implicated originally in asthma, and a variety of leukotriene synthesis inhibitors are widely used to treat asthma. 9 Thus, these inhibitors also may protect against the development of CHD, possibly providing a useful complement to drugs that target risk factors, such as lipids and blood pressure.